Add-On Durvalumab Possibly Beneficial in Muscle-Invasive Urothelial Carcinoma
Using the PD-L1 inhibitor durvalumab with neoadjuvant cisplatin/gemcitabine chemotherapy and continuing using it as adjuvant therapy after radical surgery could achieve high rates of event-free survival and downstaging, new findings show.